Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients

Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients

Abstract Survivin is an inhibitor of apoptosis. Aberrant survivin expression occurs in malignant tumors and has often been linked to unfavorable patient outcome. Here we analyzed 12 432 prostate cancers by immunohistochemistry. Survivin immunostaining was regularly expressed at high levels in normal...

Full description

Bibliographic Details
Main Authors: Franziska Büscheck, Mariam Sulimankhil, Nathaniel Melling, Doris Höflmayer, Claudia Hube‐Magg, Ronald Simon, Cosima Göbel, Andrea Hinsch, Sören Weidemann, Jacob R. Izbicki, Frank Jacobsen, Tim Mandelkow, Niclas C. Blessin, Christina Möller‐Koop, Florian Lutz, Florian Viehweger, Katharina Möller, Guido Sauter, Maximilian Lennartz, Eike Burandt, Patrick Lebok, Sarah Minner, Sarah Bonk, Hartwig Huland, Markus Graefen, Thorsten Schlomm, Christoph Fraune
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:Cancer Medicine
Subjects:
BIRC5
deletion
ERG
prostate cancer
Survivin
TMA
Online Access:https://doi.org/10.1002/cam4.2773

Internet

https://doi.org/10.1002/cam4.2773

Similar Items